Nektar’s shares fell 5.5% following the earnings release, reflecting investor disappointment primarily with cautious outlook and elongated timelines for Phase III data readouts, which delay potential commercialization and revenue generation.

• Phase III programs for REZPEG in atopic dermatitis and alopecia areata are on track, with initiation planned by mid-2026 for AD and early 2027 for AA.
• First Phase III data for atopic dermatitis expected in mid-2028, with a BLA submission targeted for 2029, indicating a lengthy clinical development timeline.
• Strong clinical data from Phase II showing deepening efficacy and durability in both indications, but no indication of accelerated approval or near-term market access.
• Company’s financial position is robust with over $1 billion in cash and investments, enabling funding through Q3 2028 without near-term capital concerns.
• Despite promising mechanistic differentiation and large target markets, investor reaction reflects uncertainty over the pace of advancement and ultimate commercial opportunity timing.